Cro services in

Lung (IPF)

Accelerate your drug development by exploring clinical pulmonary function endpoints and histopathological readouts in our BLEO-IPF and HFD-BLEO-IPF mouse models. We apply clinically relevant endpoints to ensure model translatability and the understanding of drug mode-of-action.

Why Gubra?

In-depth validated mouse models of IPF
Spirometry-confirmed lung dysfunction
Plethysmography-validated disease stratification at baseline
Automated AI-based histopathological scoring
Profile compounds using clinical trial endpoints
Tailored study design and rapid initiation

Consult with Michael Feigh

Vice President, Scientific Sales

Reach out to our experts to learn how we can move your IPF drug pipeline forward

Advance your study in
spirometry-confirmed IPF models

We offer bleomycin-induced IPF mouse models with hallmarks of lung dysfunction confirmed by spirometry and plethysmography. Our advanced study design allows for therapeutic intervention assessing anti-fibrotic efficacy.